

M A O donnell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1054202/m-a-odonnell-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138 papers	5,201 citations	41 h-index	67 g-index
147 ext. papers	5,950 ext. citations	4 avg, IF	5.46 L-index

#	Paper	IF	Citations
138	Reply by Authors.. <i>Journal of Urology</i> , 2022 , 207, 646	2.5	
137	Reply by Authors.. <i>Journal of Urology</i> , 2022 , 101097JU0000000000000235002	2.5	1
136	Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 9.e1-9.e7	2.8	3
135	Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 497-497	2.2	
134	Sequential intravesical valrubicin and docetaxel for the treatment of nonmuscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 496-496	2.2	
133	Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 573-573	2.2	
132	Phase Ib study of avelumab and taxane based chemotherapy in platinum-refractory or ineligible metastatic urothelial cancer (AVETAX study).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 503-503	2.2	1
131	VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 488-488	2.2	0
130	Overexpression of HIF1 α in Hunner Lesions of Interstitial Cystitis: Pathophysiological Implications. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002278	2.5	3
129	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology, The</i> , 2021 , 22, 107-117	21.7	53
128	Autoimmunity to urothelial antigen causes bladder inflammation, pelvic pain, and voiding dysfunction: a novel animal model for Hunner-type interstitial cystitis. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F174-F182	4.3	4
127	Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020 , 3, 318-340	6.7	14
126	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 776-785	21.7	38
125	Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2020 , 203, 902-909	2.5	36
124	Severe Infectious Complications of Intravesical Bacillus Calmette-Guérin: A Case Series of 10 Patients. <i>Urology</i> , 2020 , 137, 79-83	1.6	5
123	Combination Intravesical Therapy. <i>Urologic Clinics of North America</i> , 2020 , 47, 83-91	2.9	1
122	Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach. <i>BMC Health Services Research</i> , 2020 , 20, 686	2.9	3

121	Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 317, F90-F98	4.3	8
120	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. <i>Nature Reviews Urology</i> , 2019 , 16, 377-386	5.5	30
119	Intravesical Therapy BCG and Beyond. <i>Bladder Cancer</i> , 2019 , 5, 73-80	1	2
118	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 51-60	4	25
117	Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. <i>BJU International</i> , 2019 , 123, 35-41	5.6	12
116	Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2018 , 45, 453-457	1.7	0
115	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018 , 199, 1158-1165	2.5	56
114	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018 , 73, 738-748	10.2	77
113	Combination Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018 , 4, 503-505	5.1	12
112	Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study. <i>Scientific Reports</i> , 2018 , 8, 6573	4.9	12
111	Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2018 , 4, 512-521	5.1	8
110	Non-Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018 , 6, 2324709618806332	1.2	1
109	Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 201-207	2.8	12
108	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma 2017 , 5, 68		48
107	Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 670.e7-670.e14	2.8	14
106	Peptide-Mediated Targeting Mesoporous Silica Nanoparticles: A Novel Tool for Fighting Bladder Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2017 , 13, 232-42	4	19
105	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 145-146	1	5
104	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202	1	22

103	Inflammation and Symptom Change in Interstitial Cystitis or Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study. <i>Urology</i> , 2016 , 90, 56-61	1.6	16
102	Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2016 , 2, 215-224	1	20
101	Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. <i>PLoS ONE</i> , 2016 , 11, e0163829	3.7	11
100	Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. <i>PLoS ONE</i> , 2016 , 11, e0168772	3.7	24
99	Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer. <i>Current Urology Reports</i> , 2016 , 17, 38	2.9	22
98	Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles. <i>Cancer Nanotechnology</i> , 2016 , 7, 3	7.9	22
97	Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. <i>Prostate International</i> , 2016 , 4, 107-12	3.4	5
96	Animal Models of Urologic Chronic Pelvic Pain Syndromes: Findings From the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network. <i>Urology</i> , 2015 , 85, 1454-65	1.6	30
95	Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35	5.5	101
94	Toll-like receptor 4 and comorbid pain in Interstitial Cystitis/Bladder Pain Syndrome: a multidisciplinary approach to the study of chronic pelvic pain research network study. <i>Brain, Behavior, and Immunity</i> , 2015 , 49, 66-74	16.6	42
93	Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy. <i>BMC Urology</i> , 2015 , 15, 45	2.2	13
92	Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. <i>Bladder Cancer</i> , 2015 , 1, 105-116	1	12
91	Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. <i>Bladder Cancer</i> , 2015 , 1, 29-30	1	59
90	Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2015 , 1, 65-72	1	43
89	Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. <i>Journal of Urology</i> , 2015 , 194, 230-7	2.5	18
88	Treatment options in non-muscle-invasive bladder cancer after BCG failure. <i>Indian Journal of Urology</i> , 2015 , 31, 312-9	0.8	13
87	Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. <i>Urology</i> , 2014 , 83, 262-4	1.6	48
86	Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette-Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity. <i>Clinical and Experimental Immunology</i> , 2014 , 177, 261-8	6.2	29

85	Reply by the authors. <i>Urology</i> , 2014 , 84, 495-6	1.6	2
84	Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms. <i>Pain</i> , 2014 , 155, 1755-1761	8	51
83	Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 35.e21-30	2.8	31
82	Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 35.e15-9	2.8	73
81	New imaging techniques for non-muscle invasive bladder cancer: ready for primetime. <i>Urologic Clinics of North America</i> , 2013 , 40, 271-9	2.9	1
80	Phase I trial of intravesical recombinant adenovirus mediated interferon- β formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2013 , 190, 850-6	2.5	76
79	Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer. <i>International Journal of Urology</i> , 2012 , 19, 988-93	2.3	9
78	Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. <i>Journal of Urology</i> , 2012 , 187, 2228-35	2.5	23
77	Patient resources available to bladder cancer patients: a pilot study of healthcare providers. <i>Urology</i> , 2012 , 79, 172-7	1.6	11
76	Bladder Cancer Immunotherapy: BCG and Beyond. <i>Advances in Urology</i> , 2012 , 2012, 181987	1.6	87
75	Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon- β . <i>Journal of Urology</i> , 2011 , 185, 67-71	2.5	18
74	Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. <i>Journal of Urology</i> , 2011 , 186, 817-23	2.5	36
73	Rubin H. Flocks and colloidal gold treatments for prostate cancer. <i>Scientific World Journal, The</i> , 2011 , 11, 1560-7	2.2	4
72	Recognition and treatment of BCG failure in bladder cancer. <i>Scientific World Journal, The</i> , 2011 , 11, 602-132	2.2	22
71	Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2011 , 16, 13-26	5.4	26
70	Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 728930		35
69	Bacillus Calmette-Guérin with or without interferon β and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2010 , 184, 1915-9	2.5	95
68	Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon β therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. <i>Journal of Urology</i> , 2010 , 184, 1920-4	2.5	7

67	The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. <i>European Urology</i> , 2010 , 57, 410-29	10.2	125
66	Review of topical treatment of upper tract urothelial carcinoma. <i>Advances in Urology</i> , 2009 , 472831	1.6	6
65	Bladder cancer: narrowing the gap between evidence and practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5680-4	2.2	47
64	The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. <i>Cancer and Metastasis Reviews</i> , 2009 , 28, 345-53	9.6	43
63	Combination of BCG and interferon intravesical immunotherapy: an update. <i>World Journal of Urology</i> , 2009 , 27, 343-6	4	18
62	Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1647-55	7.4	43
61	The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. <i>BJU International</i> , 2009 , 103, 475-9	5.6	56
60	Optimizing BCG therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 325-8	2.8	11
59	Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, v. Boddi, s. Mazzoli and R. Bartoletti J Urol 2008; 180: 110-115. <i>Journal of Urology</i> , 2009 , 181, 410	2.5	3
58	Risk-adapted use of intravesical immunotherapy. <i>BJU International</i> , 2008 , 102, 1254-64	5.6	9
57	Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha. <i>BMC Immunology</i> , 2008 , 9, 4	3.7	22
56	Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. <i>Urology</i> , 2008 , 71, 297-301	1.6	73
55	Role of neutrophils in BCG immunotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 341-5	2.8	81
54	Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer?. <i>Nature Reviews Urology</i> , 2008 , 5, 526-7		7
53	Intravesical treatments of bladder cancer: review. <i>Pharmaceutical Research</i> , 2008 , 25, 1500-10	4.5	128
52	Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. <i>Clinical and Experimental Immunology</i> , 2007 , 149, 178-85	6.2	12
51	Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins. <i>BMC Cancer</i> , 2007 , 7, 204	4.8	14
50	Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. <i>European Urology</i> , 2007 , 52, 1700-8	10.2	64

49	Advances in the management of superficial bladder cancer. <i>Seminars in Oncology</i> , 2007 , 34, 85-97	5.5	33
48	Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. <i>Journal of Immunology</i> , 2007 , 179, 8418-24	5.3	36
47	Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?. <i>Nature Reviews Urology</i> , 2007 , 4, 304-5		7
46	Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin. <i>Urology</i> , 2007 , 69, 611-5	1.6	30
45	Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. <i>Clinical and Experimental Immunology</i> , 2007 , 147, 370-8	6.2	42
44	Minimally invasive management of upper tract urothelial carcinoma. <i>Current Urology Reports</i> , 2006 , 7, 23-30	2.9	5
43	The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. <i>Journal of Urology</i> , 2006 , 175, 1634-9; discussion 1639-40	2.5	114
42	Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin. <i>Journal of Urology</i> , 2006 , 175, 1197-8	2.5	4
41	Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 344-8	2.8	192
40	840: Intravesical Sequential Gemcitabine-Mitomycin Chemotherapy as Salvage Treatment for Patients with Refractory Superficial Bladder Cancer. <i>Journal of Urology</i> , 2006 , 175, 271-271	2.5	21
39	Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?. <i>BJU International</i> , 2006 , 97, 48-50	5.6	29
38	Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment. <i>Computers in Biology and Medicine</i> , 2006 , 36, 634-55	7	20
37	Treatment options for BCG failures. <i>World Journal of Urology</i> , 2006 , 24, 481-7	4	70
36	Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. <i>Urologic Clinics of North America</i> , 2005 , 32, 121-31	2.9	22
35	A novel expression of macrophage derived chemokine in human bladder cancer. <i>Journal of Urology</i> , 2005 , 173, 990-5	2.5	8
34	Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs. <i>Urology</i> , 2005 , 65, 488-92	1.6	19
33	Management of stage T1 tumors of the bladder: International Consensus Panel. <i>Urology</i> , 2005 , 66, 108-256		326
32	Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. <i>Cancer Research</i> , 2004 , 64, 3386-90	10.1	147

31	Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. <i>Clinical and Experimental Immunology</i> , 2004 , 137, 24-34	6.2	57
30	The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. <i>European Urology</i> , 2004 , 46, 670-4	10.2	33
29	Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. <i>International Journal of Cancer</i> , 2004 , 112, 653-60	7.5	30
28	Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model. <i>Journal of Urology</i> , 2004 , 172, 2414-20	2.5	10
27	Intravesical colonic pseudotumor. <i>Journal of Urology</i> , 2004 , 171, 340	2.5	1
26	Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?. <i>Journal of Urology</i> , 2004 , 172, 1056-61	2.5	31
25	Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. <i>Journal of Urology</i> , 2004 , 171, 1330-5	2.5	41
24	The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder. <i>Journal of Urology</i> , 2004 , 171, 1336-42	2.5	17
23	Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alfa-2b for superficial bladder cancer. <i>Journal of Urology</i> , 2004 , 172, 888-93	2.5	85
22	Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures. <i>Current Opinion in Urology</i> , 2004 , 14, 271-5	2.8	28
21	Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. <i>Journal of Immunotherapy</i> , 2004 , 27, 116-23	5	54
20	Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. <i>Journal of Immunotherapy</i> , 2003 , 26, 343-8	5	58
19	Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. <i>Clinical and Experimental Immunology</i> , 2003 , 131, 206-16	6.2	54
18	Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. <i>Urology</i> , 2003 , 62, 1083-8	1.6	41
17	Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 354-60	2.8	59
16	Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. <i>Cytokine</i> , 2003 , 21, 17-26	4	87
15	Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. <i>Journal of Urology</i> , 2003 , 169, 946-50	2.5	269
14	Combined bacillus Calmette-Guérin and interferon use in superficial bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 809-21	3.5	15

13	Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. <i>Immunology and Cell Biology</i> , 2002 , 80, 209-15	5	33
12	Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. <i>Clinical and Experimental Immunology</i> , 2001 , 123, 264-70	6.2	40
11	Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. <i>Journal of Urology</i> , 2001 , 166, 1300-4, discussion 1304-5	2.5	26
10	Interleukin-12. Opportunities for the treatment of bladder cancer. <i>Urologic Clinics of North America</i> , 2000 , 27, 147-55	2.9	15
9	An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines. <i>Immunology</i> , 1999 , 96, 517-23	7.8	36
8	MUTATEDRASp21 AS A TARGET FOR CANCER THERAPY IN MOUSE TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 1999 , 162, 1519-1526	2.5	6
7	BCG immunotherapy of bladder cancer: 20 years on. <i>Lancet, The</i> , 1999 , 353, 1689-94	40	353
6	Superficial bladder cancer: the role of interferon-alpha. <i>Journal of Urology</i> , 1998 , 159, 1793-801	2.5	101
5	Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. <i>Journal of Urology</i> , 1997 , 158, 2311-5	2.5	16
4	The genetic reconstruction of BCG as a new immunotherapeutic tool. <i>Trends in Biotechnology</i> , 1997 , 15, 512-7	15.1	21
3	Transitional cell carcinoma--tantalizing issues of tumor biology. <i>Journal of Urology</i> , 1996 , 156, 961	2.5	
2	Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. <i>Cancer Immunology, Immunotherapy</i> , 1996 , 42, 280-4	7.4	22
1	Intravesical immunotherapy76-88		